DrugPatentWatch Database Preview
Cefazolin sodium - Generic Drug Details
What are the generic sources for cefazolin sodium and what is the scope of patent protection?
Cefazolin sodium
is the generic ingredient in eight branded drugs marketed by Glaxosmithkline, Baxter Hlthcare, B Braun, Abraxis Pharm, Acs Dobfar, Aurobindo Pharma, Bedford, Cephazone Pharma, Dr Reddys, Facta Farma, Fresenius Kabi Usa, Hikma Farmaceutica, Hospira Inc, Qilu Pharm Co Ltd, Samson Medcl, Sandoz, Steri Pharma, Teva Pharms, West-ward Pharms Int, Lilly, and Baxter Hlthcare Corp, and is included in thirty-nine NDAs. Additional information is available in the individual branded drug profile pages.There are twenty-seven drug master file entries for cefazolin sodium. Sixteen suppliers are listed for this compound.
Summary for cefazolin sodium
US Patents: | 0 |
Tradenames: | 8 |
Applicants: | 21 |
NDAs: | 39 |
Drug Master File Entries: | 27 |
Suppliers / Packagers: | 16 |
Bulk Api Vendors: | 47 |
Clinical Trials: | 6 |
Patent Applications: | 2,688 |
Formulation / Manufacturing: | see details |
DailyMed Link: | cefazolin sodium at DailyMed |
Recent Clinical Trials for cefazolin sodium
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of British Columbia | Early Phase 1 |
Aswan University Hospital | N/A |
Federal University of São Paulo | Phase 4 |
Pharmacology for cefazolin sodium
Drug Class | Cephalosporin Antibacterial |
Medical Subject Heading (MeSH) Categories for cefazolin sodium
Synonyms for cefazolin sodium
27164-46-1 |
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)amino)-, (6R-trans)-, sodium salt |
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(((1H-tetrazol-1-yl)acetyl)amino)-, monosodium salt (6R-trans)- |
AC-13166 |
AK326218 |
AKOS015895533 |
Ancef |
Ancef (TN) |
ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER |
ANCEF IN PLASTIC CONTAINER |
ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER |
AS-12230 |
Atirin |
Biazolina |
Bor-Cefazol |
C 5020 |
C-44235 |
C08098 |
C14H13N8NaO4S3 |
CCG-40011 |
Cefabiozim |
Cefacidal |
Cefalomicina |
Cefamedin |
Cefazil |
Cefazina |
Cefazolin (sodium) |
CEFAZOLIN AND DEXTROSE |
Cefazolin sodium (JP17/USP) |
Cefazolin sodium [USAN:USP:JAN] |
Cefazolin sodium salt |
Cefazolin sodium salt, 89.1-110.1% |
Cefazolin sodium salt, Antibiotic for Culture Media Use Only |
Cefazoline sodium |
Cephazolin Sodium |
CEZ sodium |
CHEBI:3483 |
CHEMBL1200523 |
CS-4634 |
D00905 |
EINECS 248-278-4 |
EU-0100274 |
Firmacef |
FLKYBGKDCCEQQM-WYUVZMMLSA-M |
Gramaxin |
HMS1570C14 |
HMS1920K07 |
HMS2091A10 |
HMS2097C14 |
HMS2230I22 |
HMS3260H10 |
HMS3714C14 |
HMS500A16 |
HY-B1078 |
I06-1090 |
Kefzol |
KS-00000FVS |
Lampocef |
Lilly 46083 |
Liviclina |
LP00274 |
MCULE-2075772357 |
MFCD00056883 |
MLS000028706 |
MolPort-002-510-626 |
Monosodium (6R,7R)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate |
Monosodium cefazolin |
NCGC00093731-01 |
NCGC00260959-01 |
Neofazol |
NSC 291561 |
Opera_ID_1323 |
P380M0454Z |
Prestwick_975 |
Recef |
s4595 |
SCHEMBL40735 |
SK&F 41558 |
SK&F-41558 |
SKF 41558 |
SMR000058708 |
Sodium (6R-trans)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(1H-tetrazol-1-ylacetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate |
Sodium (6R,7R)-3-(((5-methyl-1,3,4-thiadiazol-2-yl)thio)methyl)-8-oxo-7-(2-(1H-tetrazol-1-yl)acetamido)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate |
sodium (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
sodium (6R,7R)-7-(2-(1H-tetrazol-1-yl)acetamido)-3-((5-methyl-1,3,4-thiadiazol-2-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
sodium 3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-7beta-[(1H-tetrazol-1-ylacetyl)amino]-3,4-didehydrocepham-4-carboxylate |
sodium 7beta-(1H-tetrazol-1-yl)acetamido-3-(2-methyl-1,3,4-thiadiazol-5-yl)thiomethyl-3-cephem-4-carboxylate |
sodium 7beta-[2-(1H-tetrazol-1-yl)-acetamido]-3-(2-methyl-1,3,4-thiadiazol-5-yl)thiomethyl-3-cephem-4-carboxylate |
sodium 7beta-[2-(1H-tetrazol-1-yl)acetamido]-3-(2-methyl-1,3,4-thiadiazol-5-yl)thiomethyl-3-cephem-4-carboxylate |
Sodium cefazolin |
sodium cefazolin(1-) |
Sodium cephazolin |
Sodium CEZ |
Sodium CEZ; SKF-41558 |
sodium;(6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
SPECTRUM1500164 |
ST024775 |
Totacef |
Tox21_500274 |
UNII-P380M0454Z |
Zolicef |
Zolin |
Zolisint |
ZX-AFC000519 |
US Patents and Regulatory Information for cefazolin sodium
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acs Dobfar | CEFAZOLIN SODIUM | cefazolin sodium | INJECTABLE;INJECTION | 065303-002 | Oct 22, 2008 | AP | RX | No | No | Start Trial | Start Trial | Start Trial | |||
Abraxis Pharm | CEFAZOLIN SODIUM | cefazolin sodium | INJECTABLE;INJECTION | 062688-005 | Aug 3, 1987 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
Sandoz | CEFAZOLIN SODIUM | cefazolin sodium | INJECTABLE;INJECTION | 062831-002 | Dec 9, 1988 | AP | RX | No | No | Start Trial | Start Trial | Start Trial | |||
Dr Reddys | CEFAZOLIN SODIUM | cefazolin sodium | INJECTABLE;INJECTION | 062988-003 | Dec 29, 1989 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
Fresenius Kabi Usa | CEFAZOLIN SODIUM | cefazolin sodium | INJECTABLE;INJECTION | 064170-002 | Mar 18, 1998 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.